Physician profile
Ryan Wolok
NPI 1215377791
$10,680.43
in general payments reported to CMS, 2019-2025
50 companies · $3,355 in 2025
The $3,355 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,279 · 2020: $440 · 2021: $918 · 2022: $1,160 · 2023: $1,693 · 2024: $1,836 · 2025: $3,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,883.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,214.04 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,715.51 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $1,128.43 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $885.15 | 2019-2025 | Evenity, Otezla, Repatha |
| Abbott Laboratories | $555.61 | 2022-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $431.60 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Abbvie INC. | $364.43 | 2025 | |
| Glaxosmithkline, LLC. | $347.53 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $265.62 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $253.00 | 2019-2025 | |
| Pfizer INC. | $248.33 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $198.38 | 2021-2025 | Rexulti |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $196.61 | 2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.18 | 2021-2025 | Jardiance, Ofev, Jascayd |
| Phathom Pharmaceuticals, INC. | $191.91 | 2024 | Voquezna |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Wolok listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.